NNC0114-0006 + placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inflammation
Conditions
Inflammation, Rheumatoid Arthritis
Trial Timeline
Sep 1, 2012 → Aug 1, 2013
NCT ID
NCT01647451About NNC0114-0006 + placebo
NNC0114-0006 + placebo is a phase 2 stage product being developed by Novo Nordisk for Inflammation. The current trial status is completed. This product is registered under clinical trial identifier NCT01647451. Target conditions include Inflammation, Rheumatoid Arthritis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01751152 | Phase 2 | Completed |
| NCT01647451 | Phase 2 | Completed |
| NCT01689025 | Phase 1 | Terminated |
| NCT01565408 | Phase 1 | Completed |
Competing Products
20 competing products in Inflammation